AAV Capsid Substitutions for Retinal and CNS Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adeno-associated virus (AAV) vectors face challenges in delivering therapeutic genes efficiently to retinal and central nervous system (CNS) cells, particularly due to issues with cell targeting and immune responses, hindering effective treatment of retinal degenerative diseases and neurologic disorders.
Innovation Solution
Development of recombinant AAV particles with specific amino acid substitutions in the AAVrh8R capsid, such as R485, R488, K528, and R533, which enhance transduction efficiency by reducing binding to heparan sulfate proteoglycans, allowing for improved delivery of heterologous nucleic acids encoding therapeutic polypeptides or nucleic acids to retinal and CNS cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type AAVrh8R capsid is used, then vector production is straightforward, but transduction efficiency for retinal and CNS cells is insufficient
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at positions R485, R488, K528, and/or R533 in the AAVrh8R capsid protein. These capsid parameter modifications enable the vector to achieve at least 10% higher transduction efficiency for retinal and CNS cells compared to wild-type, while maintaining production feasibility through defined mutagenesis protocols.
2Duration of action of moving object
If AAV vectors are used for gene delivery, then long term gene expression is achieved, but delivery efficiency to target cells is limited
Solution Approach 1:
The patent modifies capsid parameters through amino acid substitutions at R485, R488, K528, and/or R533 positions, which enhances delivery efficiency to retinal and CNS cells while preserving the AAV vector's inherent capability for long term gene expression. The modified capsid maintains serological stability and immunogenicity characteristics.
3Reliability
If AAV vectors are used for CNS gene therapy, then safety record is excellent, but delivery to affected cell populations is problematic
Solution Approach 1:
The patent introduces capsid parameter changes through amino acid substitutions at R485, R488, K528, and/or R533 positions, which specifically enhances delivery efficiency to CNS cell populations including neurons, astrocytes, and oligodendrocytes. These modifications maintain the excellent safety record of AAV vectors in clinical trials while resolving the delivery problem to CNS cells.
4Object-affected harmful factors
If AAV vectors are used for retinal gene therapy, then minimal immune responses are elicited, but transduction efficiency needs improvement
Solution Approach 1:
The patent modifies capsid parameters through amino acid substitutions at R485, R488, K528, and/or R533 positions, which enhances transduction efficiency to retinal cells including photoreceptors, retinal pigmented epithelial cells, and retinal ganglion cells. The modified capsid maintains minimal immune response characteristics while achieving at least 10% higher transduction efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified AAV particles demonstrate at least a 10% increase in transduction efficiency for retinal and CNS cells, facilitating effective treatment of ocular disorders and CNS disorders by enhancing gene delivery and expression.
Implementation Method 1
AAV vectors can mediate long term gene expression in the retina and elicit minimal immune responses making these vectors an attractive choice for gene delivery to the eye
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.